Printer Friendly

PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES NEW PRESIDENT, LITIGATION AND NEW SENIOR VICE PRESIDENT

PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES NEW PRESIDENT, LITIGATION AND NEW
 SENIOR VICE PRESIDENT
 CAMBRIDGE, Mass., June 15 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ-NMS: PBIO) announced that the board of directors today elected Noubar B. Afeyan president and chief executive officer. Dr. Afeyan, a founder of the company, has served as executive vice president/technology and operations, chief technical officer, treasurer and a director of the company since the company's inception in November 1987 and was elected founder chairman of the board of directors in April 1991.
 Dr. Afeyan succeeds James E. Coutre, whose employment by the company has been terminated but who remains a director. Daniel Wang, chairman of the board of directors, stated, "The board has full confidence in Dr. Afeyan and other members of management and their ability to carry forward the business plans of the company."
 On June 12, 1992, Coutre filed suit in the Superior Court of Middlesex County against the company and the other directors of the company alleging that Coutre had been constructively terminated as president and chief executive officer and that the directors had committed a breach of Coutre's rights under his employment contract and under the company's by-laws as a result of June 9, 1992, changes in the management reporting structure. Coutre is seeking both reinstatement and monetary damages in an unspecified amount. The company denies Coutre's allegations and intends to defend vigorously this action.
 The company also announced that Robert B. Anacone has joined the company as senior vice president of marketing and sales on May 18, 1992. Prior to joining the company, Anacone served as vice president, worldwide marketing and sales, at Serono Diagnostics, Inc., a manufacturer and marketer of clinical diagnostic instruments and reagent systems and previously served in similar capacities at Gene-Trak Systems, Inc. and Hybritech, Incorporated.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography, ImmunoDetection and Rational Surface Design.
 The company's products include a line of over 300 POROS products which consist of a family of consumable chromatography columns and media used to perform Perfusion Chromatography for both purification and analysis and the BioCAD Workstation, a computer-aided instrumentation system designed to achieve the optimal use of the company's POROS chromatography media for laboratory and development-scale purifications and for analysis.
 PerSeptive Biosystems(R) and POROS(R) are registered trademarks and Perfusion Chromatography(tm), BioCAD(tm), ImmunoDetection(tm) and Rational Surface Design(tm) are trademarks of the company.
 -0- 06/15/92
 CONTACT: Noubar B. Afeyan, president and chief executive officer, PerSeptive Biosystems, 617-621-1787
 (PBIO) CO: PERSEPTIVE BIOSYSTEMS IN: MTC SU: PER ST: MA -- NE009 -- X426 06/15/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1992
Words:479
Previous Article:THE HENLEY GROUP, HENLEY PROPERTIES TO VOTE ON PROPOSED MERGER JULY 16
Next Article:THE HALLWOOD GROUP REPORTS THIRD-QUARTER RESULTS
Topics:


Related Articles
ROBERT A. FEIN NAMED VICE PRESIDENT AND CHIEF FINANCIAL OFFICER FOR
PERSEPTIVE BIOSYSTEMS, INC. INTRODUCES ID SENSOR CARTRIDGES
PERSEPTIVE BIOSYSTEMS, INC. INTRODUCES FIRST REAL-TIME MONITORING DEVICE FOR BIOTECHNOLOGY PROCESSES
PERSEPTIVE BIOSYSTEMS AND PERSEPTIVE TECHNOLOGIES II ANNOUNCE PATENT ALLOWANCE ON DNA SEQUENCING USING MASS SPECTROMETRY
PERSEPTIVE BIOSYSTEMS REPORTS FISCAL 1995 RESULTS; PRODUCT SALES GROW 2.3X
PERSEPTIVE BIOSYSTEMS NAMES SHAUN C. LONERGAN, FORMERLY OF BOEHRINGER MANNHEIM, AS SENIOR DIRECTOR, CORPORATE DEVELOPMENT
PERSEPTIVE BIOSYSTEMS NAMES JOHN F. (JACK) SMITH AS PRESIDENT
PerSeptive Biosystems, Inc. Issues 1.25 Million Common Shares to Millipore Corporation Valued at $8 Per Share
PerSeptive Biosystems Reports Results for First Fiscal Quarter of 1997
PerSeptive Biosystems Announces New and Expanded Chemical Development and Manufacturing Services at Antisense 97

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters